|
Variable
|
ND-AML NK%high (n=34)
|
ND-AML NK%low (n=35)
|
P value
|
|---|
|
Age, years
| | |
ns
|
|
Median
| |
47
| |
|
Range
|
15–78
|
19–74
| |
|
Gender, no. (%)
| | |
ns
|
|
Male
|
20 (58.8%)
|
16 (45.7%)
| |
|
Female
|
14 (41.2%)
|
19 (54.3%)
| |
|
Hepatic or renal function, no.a
| | |
ns
|
|
Normal
|
32
|
32
| |
|
Abnormal
|
2
|
3
| |
|
WBC, 109/L
| | |
ns
|
|
Median
|
10.665
|
13.79
| |
|
Range
|
1–249.98
|
1.4–371.9
| |
|
Platelet, 109/L
| | |
ns
|
|
Median
|
34.5
|
28
| |
|
Range
|
1.87–401
|
3–167
|
56
|
|
HB, g/L
| | |
ns
|
|
Median
|
81
|
74
| |
|
Range
|
20–116
|
52–149
| |
|
PB NK, %
| | |
< 0.001
|
|
Median
|
14.1
|
5.4
| |
|
Range
|
4.2–42.9
|
2.3–21.7
| |
|
BM blasts, %
| | |
ns
|
|
Median
|
53.7
|
53.1
| |
|
Range
|
6.6–94.1
|
16.3–95.1
| |
|
BM Lymph, %
| | |
ns
|
|
Median
|
11.3
|
6.2
| |
|
Range
|
2.2–49
|
1.7–49.2
| |
|
BM NK, %
| | |
< 0.001
|
|
Median
|
19.65
|
7.6
| |
|
Range
|
12.5–43.6
|
2–11.9
| |
|
BM T, %
| | |
< 0.001
|
|
Median
|
66.5
|
77.7
| |
|
Range
|
45.6–80.4
|
46–86.2
| |
|
Cytogenetics, no. (%)
|
|
t(15;17)/PML-RARA
|
0
|
0
| |
|
t(8;21)/AML1-ETO
|
1
|
4
| |
|
inv.(16;16)/CBFb-MYH11
|
2
|
1
| |
|
CN-AMLb
|
23
|
22
| |
|
Unfavorablec
|
8
|
8
| |
|
Mutations, no. (%)
|
|
FLT3 mutations
|
15
|
5
| |
|
RAS mutations
|
6
|
6
| |
- ALT Alanine aminotransferase, AST Aspartate aminotransferase, WBC White blood cell, RBC Red blood cell, HB Hemoglobin, BM Bone marrow, ns Not significance
- P values were calculated by means of nonparametric Wilcoxon rank-sum test for continuous variables and x-square test for categorical variables
- aHepatic abnormality as defined by ALT 2.53 normal value or AST 2.53 normal value, while renal abnormality as defined by creatinine 2.53 normal value
- bCN-AML: cases having no cytogenetically identifiable abnormalities
- cUnfavorable: inv. (3)/t (3;3), t (9;22), 11q23 abnormalities, 25, 27, del (5q),del (7p), and complex karyotype
